This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ha, S.-J.
Right arrow Articles by Cho, S.-N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ha, S.-J.
Right arrow Articles by Cho, S.-N.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Tuberculosis

 Previous Article

Infection and Immunity, August 2006, p. 4954-4959, Vol. 74, No. 8
0019-9567/06/$08.00+0     doi:10.1128/IAI.01781-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Enhanced Immunogenicity and Protective Efficacy with the Use of Interleukin-12-Encapsulated Microspheres plus AS01B in Tuberculosis Subunit Vaccination§

Sang-Jun Ha,1,{dagger} Su-Hyung Park,1 Hye-Ju Kim,1 Seung-Chul Kim,2 Hyang-Ju Kang,1 Eun-Gae Lee,2 Soon-Geon Kwon,2 Byong-Moon Kim,3 Sung-Hee Lee,3 Won-Bae Kim,3 Young-Chul Sung,1*,{ddagger} and Sang-Nae Cho2,4*,{ddagger}

Division of Molecular and Life Sciences, Postech Biotech Center, Pohang University of Science & Technology, San 31 Hyoja-dong, Pohang 790-784, Korea,1 Department of Microbiology and Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, 134 Shinchon-dong, Seoul 120-752, Korea,2 Research Laboratories, Dong-A Pham. Co., Ltd., Yongin-si, Kyunggi-do 449-900, Korea,3 The International Vaccine Institute, Seoul 151-600, Korea4

Received 3 November 2005/ Returned for modification 20 December 2005/ Accepted 19 May 2006

Tuberculosis subunit vaccines codelivered with interleukin-12 (IL-12)-encapsulated microspheres (IL-12EM) are designed for a sustained release of IL-12 and could induce strong Th1 immune responses specific to Ag85A and ESAT-6. The adjuvant combination of IL-12EM plus AS01B was a more efficient way to induce a sustained Th1 immunity and protection against Mycobacterium tuberculosis.

* Corresponding author. Mailing address for Sang-Nae Cho: Department of Microbiology and Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, 134 Shinchon-dong, Seoul 120-752, Korea. Phone: 82 2 2228 1819. Fax: 82 2 392 9310. E-mail: raycho{at}yumc.yonsei.ac.kr. Mailing address for Young-Chul Sung: Division of Molecular and Life Sciences, Postech Biotech Center, Pohang University of Science & Technology, San 31 Hyoja-dong, Pohang 790-784, Korea. Phone: 82 54 279 5544. Fax: 82 54 279 2294. E-mail: ycsung{at}postech.ac.kr.

§ Supplemental material for this article may be found at http://iai.asm.org/.

Editor: J. L. Flynn

{dagger} Present address: Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, 1510 Clifton Road, Room G211, Atlanta, GA 30322.

{ddagger} Y.-C.S. and S.-N.C. contributed equally to this work.

Infection and Immunity, August 2006, p. 4954-4959, Vol. 74, No. 8
0019-9567/06/$08.00+0     doi:10.1128/IAI.01781-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»